Cardiovascular Actions of Neurotrophins

ANDREA CAPORALI AND COSTANZA EMANUELI

Division of Experimental Cardiovascular Medicine, Bristol Heart Institute, University of Bristol, Bristol, United Kingdom

I. Introduction 279

II. Neurotrophins and Neurotrophin Receptors 280
   A. Neurotrophins and pro-neurotrophins 280
   B. Neurotrophin receptors 281

III. Signaling of Neurotrophin Receptors 282
   A. Trk receptor signaling 282
   B. Transactivation of trk receptors by G protein-coupled receptor 284
   C. p75NTR signaling 284
   D. Role of proteases in p75NTR activation 285
   E. Cross-talk between neurotrophin signaling pathways activated through trk and p75NTR 286

IV. Role of Neurotrophins in Cardiovascular Development 286

V. Direct Actions of Neurotrophins on the Adult Cardiovascular System 288
   A. Neurotrophins and blood vessel growth 288
   B. Neurotrophins and vascular smooth muscle cell control 291
   C. Actions of neurotrophins on cardiac myocytes 293

VI. Neurotrophins in Cardiovascular Pathology 294
   A. Neurotrophins and cancer angiogenesis 294
   B. Neurotrophins and angiogenesis associated with chronic inflammation 296
   C. Neurotrophins in cardiovascular inflammation, atherosclerosis, and vascular wall remodeling 297
   D. p75NTR-induced impairment in postischemic reparative neovascularization in diabetes 298

VII. Neurotrophin-Based Therapeutic Perspectives 298

VIII. Summary and Perspectives 300

Caporali A, Emanueli C. Cardiovascular Actions of Neurotrophins. Physiol Rev 89: 279-308, 2009; doi:10.1152/physrev.00007.2008.—Neurotrophins were christened in consideration of their actions on the nervous system and, for a long time, they were the exclusive interest of neuroscientists. However, more recently, this family of proteins has been shown to possess essential cardiovascular functions. During cardiovascular development, neurotrophins and their receptors are essential factors in the formation of the heart and critical regulator of vascular development. Postnatally, neurotrophins control the survival of endothelial cells, vascular smooth muscle cells, and cardiomyocytes and regulate angiogenesis and vasculogenesis, by autocrine and paracrine mechanisms. Recent studies suggest the capacity of neurotrophins, via their tropomyosin-kinase receptors, to promote therapeutic neovascularization in animal models of hindlimb ischemia. Conversely, the neurotrophin low-affinity p75NTR receptor induces apoptosis of endothelial cells and vascular smooth muscle cells and impairs angiogenesis. Finally, nerve growth factor looks particularly promising in treating microvascular complications of diabetes or reducing cardiomyocyte apoptosis in the infarcted heart. These seminal discoveries have fuelled basic and translational research and thus opened a new field of investigation in cardiovascular medicine and therapeutics. Here, we review recent progress on the molecular signaling and roles played by neurotrophins in cardiovascular development, function, and pathology, and we discuss therapeutic potential of strategies based on neurotrophin manipulation.
brain protein that they named brain-derived neurotrophic factor (BDNF). Like NGF, BDNF promotes survival and neurite outgrowth of sensory neurons. Based on the homologies between the primary structures of NGF and BDNF, two years later Jones and Reichardt (124) reported the cloning of a third member of the NTs family, neurotrophin-3 (NT-3). In addition to NGF, BDNF, and NT-3, three other NTs have been identified: neurotrophin-4/5 (NT-4/5) (also known as NT-4) (120) and, limited to fishes, NT-6 and NT-7, which probably do not have mammalian orthologs (94, 189). The components of the NTs family and their signaling receptors are described in sections II and III. Since NTs were discovered by neuroscientists, initial attention focused on their actions on the developing and mature nervous system. However, strong evidence has emerged that NTs exert important cardiovascular function. Moreover, in diabetes, cardiovascular complications are usually accompanied by neuropathy, which can also be treated by NTs. It is possible therefore to envisage the use of NTs to cure diabetic cutaneous ulcers and diabetes-associated erectile dysfunction. In view of the antiapoptotic action of NGF on cardiac myocytes, NTs may be a therapeutic target for diabetic cardiomyopathy, which is characterized by exaggerated cardiovascular apoptosis, microvascular rarefaction, and neuropathy. Despite their amazing therapeutic potential, NTs are not considered ideal drug candidates. In fact, they show a poor pharmacokinetic behavior and bind, although with different affinity, two receptor types (trk and p75NTR), which can command opposite actions. Moreover, pain has been described as a side effect of recombinant NGF-based experimental therapy of diabetic neuropathy (8). However, several approaches (described in sect. vii) may allow overcoming these drawbacks.

II. NEUROTROPHINS AND NEUROTROPHIN RECEPTORS

A. Neurotrophins and Pro-Neurotrophins

NGF is a glycoprotein of 118 amino acids, consisting of three subunits (α, β, and γ complex). The α-NGF subunit appears inactive (247). The β-NGF is responsible for the NGF biological activity, while the γ-NGF is a highly specific active protease (26-kDa serine protease of the kallikrein protease group) that is able to process NGF precursor to its mature form. NGF is part of the NT family of molecules, which includes BDNF, NT-3, and NT-4/5. Fishes also possess NT-6 and NT-7. With the exception of NT-4/5, NTs are highly conserved from fishes to mammals (99), thus sharing a similar molecular mass (13.2–15.9 kDa), isoelectric points (range of 9 –10), and 50% identity in primary structure (178). NTs generally function as noncovalently associated homodimers, but at least some NT subunits are able to form heterodimers with other NT subunits. The crystal structures of β-NGF, NT-3, and NT-4/5 homodimers and the BDNF monomer have been determined (30, 172, 222). The structural hallmark of these four proteins is a characteristic arrangement of the disulfide bridges, known as the cystine knot, also identified in other secreted proteins (173). NTs are produced as 30- to 35-kDa proproteins consisting of a preprodomain, a prodomain, and a mature domain that are proteolytically cleaved to produce mature proteins (12 –13 kDa). Until recently, little consideration was paid to the NTs prodomain, which was thought to be only involved in protein folding and in regulation of NTs se-
The search for a receptor for NTs led to the discovery of two distinct ones: the tropomyosin kinase receptors (trks) and the neurotrophin receptor p75 (p75NTR) (123, 127, 138). It is now well established that survival signaling is predominantly associated with trk activation. In contrast, p75NTR, with some exceptions, has a critical role in apoptosis of neuronal and nonneuronal cells.

1. Tropomyosin kinase receptors

The trk receptors A, B, and C are typical tyrosine kinase receptors. TrkA was first cloned by two separate research groups (127, 138), followed later on by trkB and trkC (13, 127). Initially, different NTs were believed to bind preferentially to specific trk receptors: NGF to trkA, BDNF and NT-4/5 to trkB, and NT-3 to trkC. However, NT-3 can also bind to trkA and trkB (51, 252). Ligand specificity can be influenced by inserting variants in the extracellular domain of trkA and trkB. Splice variants have been described for all the three trk receptors, including deletions in the extracellular domain or intracellular truncations of the tyrosine kinase domain (242). Interestingly, the truncated trk splice variants act as dominant negative modulators of trk signaling (75, 191).

In trks, the tyrosine kinase domains are highly conserved (~80% amino acid identity) and the extracellular domains are more different (~30% amino acid identity). The extracellular domain of trk receptors is composed of three leucine-rich motifs flanked by two cysteine clusters, two immunoglobulin-like C2 type domains (Ig-C2), a single transmembrane domain, and a cytoplasmic region with a kinase domain. Binding of NTs to trk receptors occurs mainly through the Ig-C2 domains, helped by the transmembrane domain (206, 263). Like for the other tyrosine kinase receptors, phosphorylation of the cytoplasmatic tyrosines regulates their activity and provides the recruitment of adaptor molecules that mediate initiation of signaling cascades (234).

Trk receptors are present on vascular EC (34, 135, 255), VSMC (132, 184), and cardiomyocytes (36, 128, 154). The finding that vascular cells and myocytes produce and secrete NGF (34) suggests an autocrine control of cardiovascular cell functions by NTs. Unpublished data from our laboratory show that endothelial progenitor cells (EPC) from bone marrow and peripheral blood express trkB and trkA that are responsive to stimulation by BDNF and NGF. In contrast, EPC do not express trkC and are not responsive to stimulation with NT-3 (unpublished observations).

2. p75NTR

The p75NTR, which was the first receptor to be identified for NGF, belongs to the tumor necrosis factor (TNF) receptor superfamily, thus sharing the overall structure of TNF-α p55 receptor, but not the ability to bind TNF-α (123). Similar to the other TNF superfamily members, p75NTR contains four cysteine-rich motifs, a transmembrane domain, and a cytoplasmic death domain. However, unlike other TNF superfamily receptors, p75NTR does not exhibit trimerization. For eliciting its proapoptotic effect, p75NTR must be in its monomeric form, as dimerization or homomultimerization completely suppresses p75NTR-induced apoptosis (212, 271). In addition, the p75NTR death domain conformation, consisting of two perpendicular sets of three helices packed into a globular structure, differs from that of the other TNF receptor family members (152). No catalytic activity has been identified for p75NTR intracellular domain (45), and the majority of the p75NTR signals described to date are mediated by associations with cytoplasmic interactors (see below). Moreover, unlike other death receptors, including Fas/Apo-1/
CD95 and the TNF-α p55 receptor, p75\text{NTR} does not require the apoptotic adaptor molecules Fas-associated death domain (FADD) and TNF receptor-associated death domain protein (TRADD) to induce apoptosis in neural cells (273). In contrast, the interaction between p75\text{NTR} and TRADD is required for activation of NFκB, which controls the anti-apoptotic effect of NGF in breast cancer cells (77).

In contrast to the specificity of the trk receptors, each of the mature NTs binds p75\text{NTR} with equivalent affinity, but with unique kinetics (224, 225). The crystal structure of NGF in complex with the extracellular domain of p75\text{NTR} has been crystallized, revealing a stoichiometry of 2 NGF:1 p75\text{NTR}, a sort of trimeric ligand-receptor complex. The interaction between p75\text{NTR} and NGF reportedly results in conformational changes in NGF, which prevent the formation of p75\text{NTR} dimers (105). Wehrman et al. (275) recently showed that p75\text{NTR} and trkA could bind to NGF in a 1:2:1 stoichiometry (1 trkA:2 NGF:1 p75\text{NTR}). This ternary complex, in which the receptors are arranged in opposite orientations, requires that the extracellular domains of both receptors are arranged to overlap NGF protein (275). In neural cells, p75\text{NTR} and trk receptors are often coexpressed to form a complex that can be immunoprecipitated (20). p75\text{NTR}/trkA receptor association leads to the formation of a high-affinity NT binding site (108), which is abolished by mutations in the cytoplasmic or transmembrane domains of any of the two receptors (80). The affinity between NTs and trk receptors is modulated by p75\text{NTR}, which in fact increases ligand discrimination by the trk receptors (15, 20, 176).

It has been shown that, in the presence of the coreceptor sortilin (a Vps10-domain receptor), a furin-resistant mutant of pro-NGF binds to p75\text{NTR} with five times greater affinity than mature NGF, while the same mutant has no affinity for trkA (149, 193). Similarly, in the presence of sortilin, pro-BDNF binds with high affinity to p75\text{NTR}, and it does not activate trkB (256). Both pro-NGF and pro-BDNF, via p75\text{NTR}, induce cell apoptosis (149, 256). Secretion of pro-NT-3 or pro-NT-4/5 has not been reported to date. Pro-NGF and pro-BDNF reportedly bind with high affinity to a complex of p75\text{NTR} with sortilin. Both sortilin and p75\text{NTR} directly participate in binding the prodomain of pro-NGF or pro-BDNF. It has been proposed that the presence or absence of sortilin determines whether or not p75\text{NTR} acts as a death receptor (193). Recent data demonstrate that sortilin deficiency does not affect developmentally regulated apoptosis of sympathetic neurons, but it prevents their age-dependent degeneration, thus suggesting that sortilin possesses also distinct roles from apoptotic signaling (122). Finally, p75\text{NTR} has been proposed to be a dependence receptor, i.e., a receptor which responds to ligand withdrawal by caspase activation and apoptosis, as reviewed by Bredsen et al. (27).

p75\text{NTR} is scarcely expressed by EC or VSMC cultured under basal culture conditions and in healthy mice (34, 35, 229, 272). Its expression by vascular cells is induced in pathological conditions, such as ischemia, atherosclerosis, and diabetes (34, 35, 229, 272). p75\text{NTR} is also present in pericytes and perivascular mesenchymal cells in tumors (82). The expression of p75\text{NTR} by healthy or diseased cardiomyocytes has not been investigated, yet. Reports show that pro-BDNF is secreted by cells of a mouse EC line (146) and that exogenous pro-NGF engages p75\text{NTR} expressed by a transformed rat brain EC line (RBE4), thus triggering apoptosis. We recently showed that p75\text{NTR} transduction induces apoptosis of human umbilical vein EC (HUVEC), microvascular EC (HMVEC), and EPC (35). To date, no evidence exists on whether pro-NT is released from primary cultures of cardiovascular cells or exerts any action on cardiovascular cells.

In summary, mature NTs bind to trk alone or complexed with p75\text{NTR} for prosurvival signaling, while pro-NGF and pro-BDNF bind exclusively to p75\text{NTR} and trigger apoptotic events. P75\text{NTR} can induce apoptosis in the absence of a ligand. In conclusion, the ratio of trk and p75\text{NTR} receptors, the proteolytic processing of pro-NTs, and the ability of cross-linking with coreceptor are critical events governing life and death in neural and nonneural cells.

III. SIGNALING OF NEUROTROPHIN RECEPTORS

A. Trk Receptor Signaling

Trks act as typical tyrosine kinase receptors, which, following interaction with mature NT ligands, are activated by dimerization and phosphorylation in trans (115). Trk receptors are not activated by pro-NTs (149). Thus the proteases that control maturation of pro-NTs (see below) also regulate activation of trk receptors.

The cytoplasmic domains of the trk receptors contain five tyrosines (Y490, Y785, Y670, Y674, and Y675) which are essential for receptor signaling. When phosphorylated, the tyrosines constitute the binding sites for adaptor proteins that are intermediates in intracellular signaling cascades (115). In particular, Y490 and Y785 primarily recruit Shc and phospholipase C-γ (PLC-γ), respectively, while Y670, Y674, and Y675 can also engage adaptor proteins, including SH2B, adaptor protein containing PH and SH domains (APS), fibroblast growth factor receptor substrate 2 (Frs2), and growth factor receptor-bound protein 2 (Grb2) (163, 210, 251).

The major pathways activated by the trk receptors are Ras/Rap-mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK), phosphati-
dyinositol 3-kinase (PI3K)-Akt, and PLC-γ (115). Finally, activation of the small GTPase Ras in response to NTs has been shown and linked to survival and differentiation (98).

1. Ras/Rap-MAPK/ERK

NGF-induced phosphorylation of trkA at Y490 provides a recruitment site for binding of the adaptor protein Shc. Next, Shc recruits Grb2 complexed with SOS which then activates Ras (190). Activation of Ras promotes signaling through several downstream pathways, including PI3K, Raf, and p38 MAPK (266). Raf phosphorylation triggers the sequential activation of MEK1 (meiotic kinase) and/or MEK2 and then the phosphorylation of Erk1 and Erk2 by MEK1 or MEK2 (79). By a negative-feedback loop, MEK activation can stop the signaling of Ras by phosphorylating SOS to disrupt the Grb2-SOS complex (126).

The stimulation of Ras induced by trk receptors promotes only transient MAPK activation (167). In contrast, prolonged Erk activation depends on a distinct signaling pathway and requires the adaptor protein Crk, the guanine nucleotide exchange factor C3G, the small GTPase Rap1, the protein tyrosine phosphatase Shp2, and the serine threonine kinase B-Raf (96, 126). NGF-induced trkA activation leads to Frs2 recruitment at phosphorylated Y490. Frs2 phosphorylation by activated trkA provides binding sites for Grb2 and Crk (175). Association with Crk results in activation of C3G. C3G then activates Rap1, which eventually signals further downstream through B-Raf, thus resulting in a prolonged MAPK signaling (192). Recent studies identified a new ankyrin repeat-rich membrane-spanning protein (ARMS), which represents a link between trkA and Crk (119). Interaction between ARMS and Crk, which increases upon NGF treatment, modulates the activation of Rap1 and subsequently of MAPK pathway (10). The activity of Shp2, in association with Frs2, is also essential for maintaining the MAPK pathway activation by interfering with MAPK phosphatase (278). The MAPK cascade activates different transcription factors that are essential for differentiation and survival, such as cAMP response element-binding protein (CREB), Mads box transcription enhancer factor (MEF2), and Elk1 (160, 203).

The majority of the trk receptor signaling studies were developed in PC12 cells, a rat adrenal pheochromocytoma cell line, which expresses trkA and responds to NGF. Nevertheless, some studies were also performed on cardiovascular cells. In VSMC genetically modified to express high level of trkA, NGF induces a prolonged and profound activation of the MAPK cascade. The activation of this pathway by NGF increases cell migration, but not cell proliferation (141). In addition, in VSMC, NGF induces the expression of MMP-9 trough Erk1/2 activation (132). Increased MMP-9 activity contributes to the migratory response of VSMC. In partial contrast to what is observed in VSMC, NGF treatment of HUVEC causes a rapid phosphorylation of trkA, thus determining a parallel activation of ERK1/2 and subsequently an increase in proliferation (34). In primary cultures of rat neonatal cardiomyocytes, NT-3, via trkC, activated p38MAPK and ERK1/2, thus promoting cell hypertrophy (128).

2. PLC-γ

In response to receptor kinase activation by NTs, PLC-γ is recruited to a docking site surrounding phosphorylated Y785 on trkA (or equivalent sites on trkB and trkC). PLC-γ activation results in the hydrolysis of phosphatidylinositol 4,5-bisphosphate [PtdIns(4,5)P2] and generates inositol 1,4,5-trisphosphate (InsP3) and diacylglycerol (DAG) (194), with subsequent stimulation of different PKC isoforms. The proteins activated as a result of PLC-γ activation include PKC-δ, which is required for NGF-promoted induction of MEK1 and Erk1/2 (54). The PLC-γ pathway has a role in the migration of VSMC, and NGF induces a longer activation of this pathway compared with platelet-derived growth factor (PDGF)-BB (141).

3. PI3K-Akt

The serine-threonine kinase Akt plays a crucial role in the survival activity of NTs. Insulin receptor substrates (IRS-1 and IRS-2) and Grb-associated binder-1 (Gab-1) are the main adaptor proteins that mediate the association and activation of PI3K with trk receptors. Active trk receptors engage Shc, which associates with Grb2. Recruitment of Gab1 by phosphorylated Grb2 permits subsequent binding and activation of PI3K (280).

In addition, trk receptor activation results in direct phosphorylation of IRS, which recruits and activates PI3K (113). Once activated and localized to the membrane, PI3K phosphorylates phosphoinositol lipids on the D3 position of the inositol ring generating phosphatidylinositol 3,4,5-trisphosphates [PtdIns(3,4,5)P3]. These lipids serve to recruit pleckstrin homology (PH) domain-containing enzymes such as Akt and phosphoinositide-dependent kinase 1 (PDK1) to the plasma membrane. After recruitment to the membrane, Akt is phosphorylated and consequently activated by PDK (166). In turn, Akt controls the activities of several proteins through phosphorylation. Between the varieties of downstream Akt substrates, Bad, caspase-9, IκB-kinase, and Foxo transcription factors are involved in the antiapoptosis effects of Akt. Cell type-specific Akt substrates also exist, such as endothelial nitric oxide synthase (eNOS), which regulates nitric oxide (NO) biosynthesis in EC, EPC, and cardiomyocytes (236, 241). Numerous reports show that the PI3K/Akt signaling pathway is critically involved in EC survival and migration and in angiogenesis (243). We demon-
Neurons or cardiovascular cells. The mechanisms behind trk receptor transactivation are not completely understood and have not yet been investigated in cardiovascular cells. Because of the many actions of GPCR on the cardiovascular system and on progenitor cells, this line of investigation may lead to important findings.

C. p75NTR Signaling

The function of p75NTR varies considerably depending on the cellular context in which the receptor is expressed. To date, in vascular cells, p75NTR has only been implicated in apoptosis (35, 135, 139) and in EC cycle arrest (35). The first evidence of p75NTR-mediated apoptosis came from Rabizadeh et al. (211), who showed that p75NTR overexpression induces apoptosis of neural cells in the absence of ligand. We have recently confirmed this by showing the dramatic apoptotic responses of EC and EPC following transduction with p75NTR (35). In our hands, p75NTR-transduced HUVEC (but not HUVEC transduced with control gene) can respond to an exogenously added furin-resistant pro-NGF mutant with a modest increase in apoptosis (unpublished data), but exogenously added ligand is not necessary to initiate a robust apoptotic response (35). In contrast, in VSMC genetically manipulated to express p75NTR and lacking trk receptor expression, treatment with NGF or NT-3 causes a dose-dependent increase of apoptosis (272). It has been proposed that p75NTR overexpression produces cell death in a ligand-dependent fashion as well as following ligand withdrawal. The decision between ligand-dependent or ligand-independent apoptosis might be related to the cellular context, as well as the presence of trk receptors and of different adaptor proteins (reviewed in Ref. 27). The signaling mechanisms used by p75NTR have remained elusive. The lack of catalytic activity in the cytoplasmic domain of p75NTR suggests that interacting proteins carry out the signaling of this receptor. Two p75NTR regions are crucial in protein-protein interaction: the death domain (273) and the juxtamembrane intracytoplasmatic domain named “chopper” (56). As reviewed by Dempsey et al. (63) and Vilar et al. (267), several different p75NTR interacting molecules, with and without catalytic activity, have been identified. Noncatalytic interactors include scaffolding- and adaptor-like molecules, such as caveolin-1, NADE (p75NTR-associated cell death executor) and TNF receptor-associated factor (TRAF) 4 and 6. Transcription factors containing zinc-finger domains, such as NT receptor-interacting factor 1/2 (NRIF1/2), Schwann cell factor 1 (SC-1), and NRAGE (p75NTR-interacting MAGE homolog) can also bind the p75NTR intracellular domain. P75NTR interactors with catalytic activity include serine-threonine kinases involved in interleukin and NFκB signaling, such as interleukin-1 receptor-associated kinase (IRAK) and...
receptor-interacting protein-2 (RIP2), the protein tyrosine phosphatase Fas-associated phosphatase-1 (FAP-1), and the small GTPase RhoA. Finally, brain-expressed X-linked 1 (Bex-1) has been recently discovered to interact with p75NTR in competition with RIP2 (267). How these p75NTR-interacting proteins connect to downstream signaling pathways and cellular responses has not been extensively elucidated. Moreover, reports linking adaptor proteins to p75NTR actions on mature or progenitor cells of the cardiovascular system are still missing, thus calling for significant investigation. In noncardiovascular cells, ceramide production (67), activation of the transcription factor NFκB (39), and the c-Jun kinases JNK1-3 (40, 86, 102) have been found downstream to p75NTR. One hallmark in p75NTR-mediated apoptosis is reportedly the activation of the JNK signaling cascade (284). Nevertheless, we could never observe increased JNK phosphorylation in p75NTR-transduced HUVEC undergoing apoptosis (unpublished observations). Downstream to JNK, events involved in p75NTR-induced apoptosis include activation of p53, direct phosphorylation of Bad, release of cytochrome c from mitochondria, and activation of caspases 9, 6, and 3 (19, 196). P75NTR-induced activation of JNK cascade was described to be mediated through Rac GTPase (102). Genetic deletion of TRAF6 prevents p75NTR activation of JNK signaling, thus inhibiting apoptosis in sympathetic neurons (283). NRIF has been proposed to interact with TRAF6 to induce the activation of JNK downstream to p75NTR (41, 92). It has been proposed that NRIF nuclear translocation is necessary for p75NTR-induced cell death. This cytoplasmatic-nuclear shuttling is modulated by TRAF6-mediated polyubiquitination of NRIF at lysine-63 (88, 156). It was reported that NRIF is ubiquitinated following the γ-secretase cleavage of p75NTR in response to proapoptotic ligands and that NRIF ubiquitination is essential for its nuclear entry (129). TRAF-6 also appears to be involved in p75NTR-mediated NFκB activation (134). N Rage interacts with p75NTR to mediate NT-induced cell death through a mechanism that involves cell cycle arrest, JNK activation, and caspases activation (130). Bronfman et al. (28) reported that binding of NGF induces p75NTR internalization and the subsequent association of p75NTR with N Rage in recycling endosomes. TRAF-6 also appears to be involved in p75NTR-mediated NFκB activation (134). The possible interactions of p75NTR with NRIF or TRAF-6 and the activity of N Rage on cardiovascular cells have not been investigated, yet.

In noncardiovascular cells, the interaction of p75NTR with N Ade has also been shown to induce apoptosis (179), which is probably modulated by an interaction between N Ade and 14–3–3 protein (136). The effect of p75NTR on survival of noncardiovascular cells is duplex. In fact, several studies have provided evidence that p75NTR can promote survival through activation of NFκB (39, 64, 91, 284). This signaling pathway is activated by NGF, but not BDNF or NT-3 (39), and requires several proteins, including TRAF-6, p62, IRAK, and RIP2. The complex between TRAF6, IRAK, and p62 is necessary for the phosphorylation of IKB and subsequent activation of NFκB (165). Finally, p75NTR mediates sphingomyelin hydrolysis and production of ceramide following NT binding (66). Ceramide has been shown to promote both apoptotic and prosurvival pathways initiated by p75NTR activation (248).

SC-1 and Bex-1 have been involved in the action of p75NTR on cell cycle. The transcription factor SC-1 was the first molecular link between p75NTR and the regulation of cell cycle identified. Following the binding of NGF to p75NTR, SC-1 translocates to the nucleus and induces cell cycle arrest (50). A recent study reports that SC1 forms a complex with histone deacetylases to regulate the levels of cyclins E and B in response to NGF (49). The exact function of Bex-1 is not clear. It was recently described that, in PC12 cells, Bex1 levels oscillated during the cell cycle and may contribute to p75NTR-induced cell cycle arrest (267). Bex-1 looks to mediate p75NTR-induced cell cycle arrest independently to NGF binding (267). We have found that transduction with p75NTR promotes cycle arrest in HUVEC in the absence of exogenously added ligand (35). However, NGF is present in the conditioned culture medium of HUVEC (34). The expression of Bex1 or SC-1 in cardiovascular cells has not been investigated. If Bex1 and SC-1 are present in p75NTR-transduced HUVEC, they may play a role in the antiproliferative effect observed in the absence of added ligands. This hypothesis should be investigated.

Finally, p75NTR also modulates the small GTPase RhoA, a member of the Rho family of proteins that control the organization of the actin cytoskeleton. In neurons, in the absence of NTs, p75NTR interacts with RhoA and activates it to inhibit axonal growth. In contrast, NGF causes dissociation of RhoA from p75NTR, thus blocking RhoA activity and leading to axonal growth (282). In particular, p75NTR facilitates the release of RhoA from inhibition by RhoGDI, thus enabling RhoA to be activated. The activated RhoA then interacts with growth-inhibitory proteins, such as Rho kinase (ROCK) to suppress axonal growth and regeneration (281).

At this stage, it is essential to understand what are the intracellular interactors of p75NTR in mature and progenitor cardiovascular cells either in culture or in vivo. This is a prerequisite toward clarification of the signaling pathways emanating from p75NTR in these cell types.

D. Role of Proteases in p75NTR Activation

Similarly to Notch (62), also p75NTR activation is subject to regulated intramembrane proteolysis (RIP)
(125). The first cleavage of RIP is taken over by the metalloproteinase ADAM17/TACE that leaves a membrane-bound COOH-terminal fragment (CTF) and liberates the extracellular domain (ECD). This first cleavage is permissive for the subsequent one. The second cleavage is mediated by the γ-secretase and occurs in the p75NTR-CTF intramembrane region to release a soluble intracellular domain (ICD) (125). It has been reported that p75NTR cleavage is stimulated by different activators, such as phorbol esters, NGF, and pro-NGF (129, 208, 264). Until now, p75NTR cleavage has not been investigated in cardiovascular cells. It is now clear that the Notch ICD (NICD), which is also generated by γ-secretase, regulates gene expression by forming transcriptionally active complexes (239). Although soluble p75NTR-ICD has been localized in expression by forming transcriptionally active complexes (228). 

Caveolin enhances p75NTR-trk complex formation (23). In addition, caveolin overexpression avoids NGF-induced differentiation of PC12 through a direct inhibition of trk receptor activity. This inhibition reportedly correlates with an increased ability of NGF to induce sphingomyelin hydrolysis through p75NTR (22). Interestingly, caveolin-1 is highly expressed in EC, VSMC, and monocytes (EPC are a subpopulation of monocytes). Depending on the cell type and the pathological context, caveolin-1 may positively or negatively influence the development of vascular disease and angiogenesis (reviewed in Ref. 85). Further studies are necessary to understand the nature of interaction between NT receptors and caveolin in cardiovascular cells.

Finally, also the p62-TRAF-6-IRAK complex involved in the p75NTR-activated NFRK pathway functions as a scaffold for association of trk receptors and p75NTR (277).

IV. ROLE OF NEUROTROPHINS IN CARDIOVASCULAR DEVELOPMENT

NTs and their receptors are expressed by the developing heart and vessels (18, 233). Seminal studies performed in global knock-out mice implicated NTs in the in utero development of the heart and the coronary vasculature. In particular, BDNF deficiency reduces endothelial cell-cell contact in the mouse embryonic heart, thus leading to intraventricular wall hemorrhage and depressed cardiac contractility (see Fig. 1I) (70). Similarly, trkB<sup>−/−</sup> mice show a marked reduction of blood vessel density and increased number of TUNEL-positive apoptotic EC, predominantly in the subepicardial region of the developing heart (269). NT-3<sup>−/−</sup> mice develop abnormalities of the great vessels, including developmental delay in the primitive myocardialization of the truncus arteriosus (69, 257). Moreover, genetic deficiency of either NT-3 or trkC impaired cardiac morphogenesis in mice (see Fig. 1, II and III) (69, 258). Some of these developmental defects appeared as early as embryonic day 9.5, which is before the onset of cardiac innervation in mice, thus suggesting the existence of a direct control of NTs on cardiovascular development (257). Cardiovascular abnormalities are also present in transgenic mice overexpressing a truncated trkC receptor, which acts as a dominant negative (198). These findings were later expanded in a chicken model of heart development, which demonstrated that NT-3 and trkC are coexpressed by developing cardiomyocytes to mediate their proliferation (154). The series of these developmental studies importantly introduced the concept that NTs have direct effects on cardiovascular cells, which express trk receptors.

During prenatal development, p75NTR is present in EC and VSMC of large blood vessels, as demonstrated by immunohistochemistry for p75NTR together with the
VSMC marker α-actin and the EC marker PECAM-1 of wild-type murine embryos (at E11.5) (268). Studies aimed at understanding the effect of p75NTR deficiency on vascular development were attempted by von Schack et al. (268), who decided to disrupt exon IV to produce a global null mouse lacking all p75NTR gene products (p75NTRExonIV−/−). The p75NTRExonIV−/− mice suffer from significant death at late gestational stages or around birth. The vascular system of p75NTRExonIV−/− embryos is defective. The dorsal aorta has a thinner wall and
increased lumen diameter. Many $p75^{NTRExonIV/−}$ embryos show vascular ruptures and blood cell leakage (268). Unfortunately, this genetic model was later proven inappropriate, as it produced a fragment of the $p75^{NTRExonIV}$ protein that contains a portion of the extracellular domain and the transmembrane and intracellular domains. This protein derives from aberrant expression of a $p75^{NTRExonIV}$ mRNA that is initiated 3’ to the inserted pGK-neo cassette and activates the proapoptotic $p75^{NTRExonIV}$ signaling cascades resulting in JNK phosphorylation and cleavage of pro-caspase-3 (202). There is another global $p75^{NTRExonIV}$ knock-out model available, which was created by deleting $p75^{NTRExonIII}$ (148). This mouse has been used by many laboratories, but, unfortunately, also $p75^{NTRExonIII/−}$ mice are not optimal to understand the involvement of the receptor in cardiovascular development. In fact, $p75^{NTRExonIII/−}$ mice maintain expression of an alternatively spliced form of $p75^{NTRExonIII}$ ($s-p75^{NTRExonIII}$) (202, 268).

Mice with global knockout for either $trkA$ or NGF gene can develop to birth, but are smaller and die early, possibly because of their defective nervous phenotype (58, 246). Their cardiovascular phenotype has not been studied. By an interesting “reverse conditional” gene targeting strategy, $trkA$ function was restored specifically in the nervous system to produce mice lacking $trkA$ in non-neuronal tissues, only. These mice are viable and appear grossly normal (53); however, their cardiovascular system was not specifically investigated either during prenatal development or in adulthood. Transgenic mice expressing a neutralizing antibody against NGF (alphaD11) were also developed. These mice show no gross phenotype at birth, even if they later develop skeletal muscle dystrophy, apoptosis in the spleen, and Alzheimer-like neurodegeneration (37, 226). Also for this model, a targeted analysis of the cardiovascular system is still missing.

Additional investigations demonstrated the more obvious concept that NTs can influence cardiovascular development through nerve-mediated actions, as in the case of NGF transgenic mice, which presented cardiac hyperinnervation (104). The generation of new animal models lacking or overexpressing the genes for NT receptors in selected cardiovascular cells should allow elucidating the direct cardiovascular actions of NTs during development and adulthood. An alternative interesting approach that can help obtain information on the developmental actions of candidate molecules is to test their differentiative activity on embryonic and fetal stem cells. Accordingly, Shmelkov et al. (244) prompted the effect of BDNF on CD133$^+$ stem cells extracted from the human fetal liver. They found that BDNF given alone or together with VEGF-A is able to address CD133$^+$ stem cells to differentiate toward the endothelial lineage as well as giving rise to beating cardiomyocytes, which, once transplanted into the mouse ear, are able to generated electrical action potentials detectable by electrocardiogram tracing (244). The finding that BDNF promotes differentiation into the angiomyogenic lineage prompts new investigations aimed to understand the potential of BDNF and other NTs to improve preparation of cardiomyocytes and EC from embryonic stem cells and from adult stem cells of different sources, such as the bone marrow or adipose tissues. It is worth noting that BDNF, NT-3, and NT-4/5 are produced by human embryonic stem cells (hESC) to mediate their survival by an autocrine mechanism, which engages trk receptors and initiates the PI3K/Akt pathway without affecting MAPK (209). Moreover, it is relevant that addition of NTs to hESC cultures induces a 36-fold improvement in their clonal survival leaving the cells with full conserved developmental potency (209). Furthermore, when hESC are cultured in the presence of NTs on three-dimensional scaffolds, they can form vascular structures throughout the engineered tissues (150).

V. DIRECT ACTIONS OF NEUROTROPHINS ON THE ADULT CARDIOVASCULAR SYSTEM

A. Neurotrophins and Blood Vessel Growth

The development of a complex mature vascular system is a process that requires EC proliferation and migration as well as the fundamental support of periendothelial cells. These accessory cells such as pericytes and VSMC interact with EC to form the complex network of capillaries, arterioles, arteries, and veins. Blood vessels in the embryo form through vasculogenesis, which is in situ differentiation and maturation of vascular cell precursor cells that assemble into a vascular network, and angiogenesis (221). The term angiogenesis was first used to describe the growth of endothelial sprouts from preexisting postcapillary venules. More recently, this term has been used to generally indicate the growth and remodeling process of the primitive vascular network into a complex network. This can involve the enlargement of preexisting vessels which sprout and divide or the formation of capillaries through transendothelial cell bridges (2, 107) as well as intussusception, also known as splitting angiogenesis, where the capillary wall extends into the vascular lumen to split a single vessel in two (65). Angiogenesis and vasculogenesis can also occur in the adult organism. As reviewed by Carmeliet (38), postnatal angiogenesis occurs physiologically in the cycling ovary and the placenta. Moreover, angiogenesis is reactivated during wound healing and repairs and under pathological conditions, such as cancer, ocular, and inflammatory disorders (38). In 1997, Asahara et al. (11) reported that adult bone marrow-derived CD34$^+$ hematopoietic progenitor cells, which can be purified from the mononuclear fraction of peripheral blood cells, could differentiate ex vivo to an endothelial phenotype. These cells, which Ashara named...
"EPC" (endothelial progenitor cells), showed expression of various endothelial markers and incorporated into new vessels at sites of ischemia (11). Further studies demonstrated that bone marrow and peripheral blood CD133+ hematopoietic stem cells also differentiate to EC in vitro (89, 205).

NGF was the first NT to be implicated in postnatal angiogenesis (231). Proliferation, survival, and migration/invasion of EC are all essential to the angiogenesis process. HUVEC and pig aortic EC have the mRNA for NGF and its receptors trkA and p75NTR (34, 213), although the protein expression level of p75NTR is scarce in normally cultured HUVEC (35) and in capillary EC belonging to healthy murine limb muscle (229). In 2001, Raychaudhuri et al. (216) first described the proliferative action of NGF on human dermal microvascular EC, a finding which was later confirmed in HUVEC (34), human choroidal EC (250), and rat brain EC (177). The proliferative action of NGF on EC is reportedly mediated by Erk activation downstream of trkA (34). NGF, via trkA, supports EC survival in vitro and in vivo, an action which is, at least in part, mediated by increased VEGF-A (78, 95, 229). NGF is a chemoattractant for EC, able to induce migration of human and pig aortic EC (68, 213). The chemotactic action of NGF on pig aortic EC is reportedly mediated by the simultaneous activation of the PI3K/Akt and Erk signaling pathways (213). NGF also induces HUVEC invasion through a collagen I-coated filter, by activating MMP-2 (200). The chorioallantoic membrane (CAM) of the chicken embryo and the avascular corneal micropocket of rodent eye are among the primordial assays developed to screen the capacity of molecules to promote blood vessel growth in vivo (103). NGF induces a dose-dependent angiogenic response in the rat cornea (240), and it additionally stimulates blood vessel growth in the chicken and quail CAM (34). NGF-induced CAM neovascularization is partially affected by anti-VEGF-A antibodies, thus suggesting the involvement of VEGF-A in NGF-induced angiogenesis (34, 145). In contrast to trk actions, ligand (NGF and pro-NGF)-dependent activation of p75NTR reportedly induces EC death (135). Moreover, a recent study from our laboratory described impaired proangiogenic capacity of p75NTR-transduced HUVEC (35). Figure 2 illustrates enhanced EC apoptosis and defective EC cycle, migration, and capillary-like structure formation following gene transfer-induced p75NTR expression. Figure 3 summarized the actions and underpinned molecular pathways which activation of trks and p75NTR stimulates in EC.

Our group was the first to identify the strong angiogenic action exerted by NTs in a mouse model of limb ischemia, which is instrumental to study the effect of endogenous and exogenous factors on postischemic reparative neovascularization (78). In this model, as illustrated by Figure 4, we showed that NGF is an autocrine proangiogenesis factor, which becomes upregulated together with its trkA receptor following insurgence of ischemia (Fig. 4A) to promote the growth of new capillaries in ischemic muscles. In fact, blockade of endogenous NGF by a neutralizing antibody disrupts the angiogenesis response to muscular ischemia (Fig. 4B), while exogenous NGF supplementation to ischemic muscles enhances the spontaneous formation of capillaries and arterioles in ischemic muscles (Fig. 4, C and D) and accelerates blood flow recovery (Fig. 4G) (78, 229). NGF actions in ischemic muscles extend to include antiapoptosis of capillary EC and skeletal myocytes (Fig. 4, E and F) (78, 229). NGF appears to induce angiogenesis through trkA by increasing the expression level of VEGF-A (33, 78, 101, 230) and possibly VEGF receptors (101) and activating the Akt intracellular pathways leading to NO production and upregulation of MMP-2 expression (78, 200, 213). In fact, in the limb ischemia angiogenesis model, NGF-induced angiogenesis was prevented by a neutralizing antibody for VEGF-A, inhibition of NO synthase (by l-NAME), or gene transfer with a dominant negative mutant form of Akt (Fig. 4H) (78). As reported above, also Erk was implicated in NGF-induced EC proliferation and migration, which are processes potentially utilitarian to angiogenesis. We have more recently found that NGF gene delivery to the infarcted heart of mice and rats can be used to increase capillary density and inhibit EC apoptosis in the peri-infarct area (unpublished data), which may have important therapeutic implications. Moreover, NGF promotes angiogenesis in healing cutaneous wounds, thus favoring cicatrization (95).

Some of the angiogenesis-related actions of NGF have been later proved to be shared by BDNF. In 2000, Nakahashi et al. (182) found BDNF mRNA and protein in HUVEC. Kim et al. (135) confirmed BDNF expression by EC and additionally showed that EC express trkB and that the level of BDNF transcript is upregulated by hypoxia in EC, a feature which is compatible with a proangiogenesis action of the BDNF. The hypoxia-mediated regulation of BDNF in EC was confirmed by Wang et al. (270) using a mouse brain microvascular EC line (bEnd.3 cells). BEnd.3 cells respond to either sustained or intermittent hypoxia with increased production and release of BDNF in the culture medium. Endogenous BDNF promotes EC survival, while exogenously added recombinant protein stimulates in vitro angiogenesis, via PI3K/Akt (135). Similarly, to NGF, also BDNF, via trkB, reportedly upregulates VEGF-A expression level. According to Nakamura et al. (183), this action is induced by PI3K and hypoxia-inducible factor 1 alpha (HIF-1α). In turn, VEGF-A can upregulate BDNF mRNA level, as observed in myometrial microvascular EC (276). Inhibition of VEGF receptor 2 significantly decreases BDNF expression in brain EC (47). Given the knowledge that VEGF-A, via Akt phosphorylation of eNOS, stimulates NO production from EC (1, 87) and that NO reportedly upregulates BDNF (46), it is possible that eNOS-derived NO is involved in the VEGF-A-
induced increase in BDNF. Kermani et al. (131) tested the potential of angiogenesis gene therapy with BDNF in the ischemic limb mouse model. Similar to what was already observed for NGF, BDNF expression is upregulated in ischemic limb muscles to induce phosphorylation of vascular trkB. Gene transfer-mediated BDNF overexpression increases capillary density of ischemic muscle, thus accelerating blood flow recovery (131). Interestingly, intravenous injection of an adenovirus carrying the BDNF gene induces the mobilization of Sca-1+/H11001CD11b+/H11001hematopoietic progenitor cells in the peripheral blood of mice. The finding, which is in line with the presence of trkB and other NT family components in the bone marrow (142), was confirmed in vitro by studying the migration toward BDNF of total bone marrow cells. In this system, BDNF proved to predominantly attract MOMA-2+/H11001CD45+ cells. In line, ischemic muscle transduced with BDNF showed increased infiltration of MOMA-2+/CD45+ cells (131). The report by Kermani et al. (131) was the first to suggest a supportive effect of NTs on postnatal vasculogenesis. However, a more exhaustive definition of adult progenitor cell populations responding to BDNF and NTs is necessary. In addition, Kermani and colleagues (78, 131) did not demonstrate that increased circulating MOMA-2+/Sca-1+ cells and enhanced infiltration of MOMA-2+/CD45+ cells effectively contribute to BDNF-induced neovascularization of ischemic limb muscles. Unlike NGF, the proangiogenic actions of BDNF are not hampered by neutralizing VEGF. In addition, BDNF increases capillarization, but it has no effect on arterioles or small arteries, although this latter finding is apparently difficult to reconcile with BDNF-induced improved blood
flow recovery (78, 131). Another difference from NGF is that BDNF does not induce angiogenesis in the corneal pocket model, which may be explained with the absence of trkB in EC belonging to this district (131, 240). Rather, BDNF induces angiogenesis in both the Matrigel plug and the mouse ear models, with its responses being comparable to those elicited by VEGF-A (131). NT-4/5, which is an additional ligand of trkB, is also able to promote angiogenesis in the Matrigel model (131). Recent findings from our laboratory suggest that BDNF gene transfer promotes neovascularization of the peri-infarct myocardium (unpublished data). Our data are in line with the report that BDNF potentiates basic fibroblast growth factor (bFGF)-induced angiogenesis and improves cardiac function following myocardial infarct (157). Moreover, BDNF induces blood vessel growth in transected adult rat thoracic spinal cord, as demonstrated when using BDNF to impregnate freeze-dried poly(D,L-lactic acid) macroporous guidance scaffolds (201). It is also possible, even if not yet demonstrated, that BDNF plays a role in brain angiogenesis induced by physical exercise. In fact, the levels of brain BDNF and VEGF-A increase and angiogenesis develops in the brain of exercising mice (55). It has been demonstrated that blocking VEGF-A inhibits exercise-induced brain angiogenesis (55). As, out of the brain, BDNF is able to upregulate VEGF-A and vice versa (183, 276), the involvement of BDNF in brain angiogenesis is plausible.

The main receptor for NT-3, trkC, is not expressed by HUVEC, which are the most popular model of EC used by angiogenesis laboratories. This fact possibly explains why NT-3 has not been investigated as a potential angiogenesis mediator. Nevertheless, trkC is highly expressed by human veins and mouse capillary EC (unpublished data). Unpublished data from our laboratory show that adenovirus-mediated NT-3 gene transfer to murine ischemic hindlimbs stimulates the proliferation of capillary EC, thus increasing capillary density (unpublished data). These findings apparently contradict a previous investigation which proved NT-3 to inhibit the mitogenic activity of rat brain EC (255). Gene therapy with NT-3 can promote blood flow recovery to the ischemic foot (unpublished data). Western blot analyses of NT-3-transduced muscles revealed increased levels of phosphorylated trkC, Ser-473-phosphorylated Akt, and Ser-1177-phosphorylated eNOS. Increased eNOS protein level and NO production following stimulation with NT-3 were also reported in rat brain EC (255). In contrast to what was found for NGF, the content of VEGF-A mRNA or protein is unchanged by overexpressing NT-3 (unpublished data). The scheme in Figure 5 summarizes the potential of NTs/trks to induce blood vessel growth by angiogenesis and vasculogenesis.

B. Neurotrophins and Vascular Smooth Muscle Cell Control

NGF, BDNF, and NT-3 are expressed in the wall of the aorta and pulmonary artery of embryonic and postna-
tal rat. The level of NT-3 in blood vessels is relatively constant from the embryonic to adult stage, while levels of BDNF increase and those of NGF decrease (233). Other studies show discrepancies of results about BDNF expression, reporting only faint BDNF mRNA expression in the heart (109, 164, 259).

Cultured VSMC express NTs and their receptors and secrete NTs in a regulated manner (71, 184, 185, 261). VSMC possess proprotein convertases (PC), such as furin, PC5, and PC7, which are devoted to the maturation of pro-NTs in their active form (249). NGF does not stimulate VSMC proliferation, but it is a potent chemotactic...
agent for human aortic VSMC (71). NGF-induced VSMC migration is mediated by PI3K and Akt, as it can be blocked by either LY294002 or wortmannin (141). The NGF/trkA receptor signal, via Shc/MAPK pathway, induces MMP-9 expression in primary rat aortic VSMC and in a VSMC line genetically manipulated to express trkA. MMP-9 may favor VSMC migration and invasion (132). Stimulation with NGF, NT-3 and, to a less extent, BDNF of p75NTR-expressing VSMC promotes apoptotic death (272). The role of trkA in VSMC apoptosis is still controversial (26, 272).

Figure 6 illustrates the actions and underpinned molecular pathways that could be stimulated by NTs in VSMC.

C. Actions of Neurotrophins on Cardiac Myocytes

The first evidence of secretion of neurotrophic factors by heart cells was obtained in 1979, when Eberdal et al. (73) showed that heart explants support neurite extension from sensory neurons in vitro. All NTs are expressed by the mammalian heart, as demonstrated by different techniques (112, 164, 238, 259). Truncated form of trkB and trkC receptors have also been reported in endothelial cells and skeletal myocytes in ischemic adductor muscles. NGF or vehicle was intramuscularly injected every day starting on the day of femoral artery excision. Muscles were harvested 5 days later. Apoptosis found at the level of capillary endothelial cells (ECs) and skeletal myocytes in ischemic adductor muscles were repeated over 5 or 14 days, starting from the day of ischemia induction. Capillary (C) and arteriole (D) density was evaluated 14 days thereafter. Microvascular density of untouched adductors (open column) is shown as a reference. Neovascularization was potentiated at arteriole and capillary level by 14-day NGF treatment. Five days of treatment exerted an effect on arteriole growth only. Values are means ± SE (at least n = 8) improved perfusion recovery compared with vehicle (open symbols, n = 10). Values are means ± SE (n = 4 mice per group). §P < 0.05 vs. V. G: supplementation of NGF to ischemic limb muscles improves postischemic blood flow recovery. Line graph shows the effect of NGF supplementation for 14 days on foot postischemic BF recovery, expressed as ischemic to contralateral BF ratio. NGF (full symbols, n = 8) improved perfusion recovery compared with vehicle (open symbols, n = 10). Values are means ± SE. *P < 0.05 vs. time 0. 

Stimulation with NGF, NT-3 and, to a less extent, BDNF of p75NTR-expressing VSMC promotes apoptotic death (272). The role of trkA in VSMC apoptosis is still controversial (26, 272).

We have recently identified that NGF is an autocrine prosurvival factor for cardiomyocytes (36). Rat neonatal cardiac myocytes use trkA to secrete NGF, which provides paracrine and autocrine protection against hypoxic/ischemic injury (25, 272). The role of trkA in VSMC apoptosis is still controversial (26, 272).

Figure 5. Schematic representation of mechanisms by which NTs stimulate blood vessel growth. NGF promotes angiogenesis through trkA by increasing the expression level of VEGF-A, and through activation of the Akt intracellular pathways leading to NO production and up-regulation of matrix metalloproteinase (MMP)-2 expression. Some of the angiogenesis-related actions of NGF have been later proven to be shared by BDNF. Moreover, BDNF induces the mobilization of trkB-Sca1bone marrow progenitor cells, suggesting a promotional role of BDNF on postnatal vasculogenesis, although this hypothesis needs to be validated.
cardiomyocytes express and release NGF (36, 117) and possess trkA (36) (Fig. 7). Moreover, cardiomyocytes undergo apoptosis when treated with a neutralizing antibody for NGF or the trkA inhibitor K252a (Fig. 7B). Furthermore, NGF expression in cultured cardiomyocytes increases following either hypoxia/reoxygenation (H/R) or incubation with high ANG II levels, two conditions inducing cardiomyocyte apoptosis. When, under each of those conditions, the NGF/trk receptor signaling is inhibited, apoptosis is dramatically augmented, thus reinforcing the idea of an antia apoptotic role for this NT (36).

Increased NGF level obtained by either gene transfer or supplementation with a NGF recombinant protein protects neonatal and adult cardiomyocytes from apoptosis induced by either H/R (Fig. 7C) or ANG II (36). The prosurvival signal of NGF in cardiac myocytes encompasses Akt phosphorylation and the nuclear/cytosolic shuttling of Akt and Forkhead transcription factors Foxo-3a and Foxo-1 (36). Finally, in a rat model of myocardial infarction, NGF gene transfer supports cardiomyocytes survival (Fig. 7D) (36). Akt promotes both survival and (physiological and pathological) hypertrophy of cardiomyocytes (reviewed in Ref. 42). Anversa and Sussmann (42) proposed the theory that extranuclear Akt plays the double role of promoting survival and growth by acting on several redundant downstream targets, including Bad and glycogen synthase kinase-3, whereas nuclear Akt combats apoptosis without interfering with the control of cell size. Indeed, the knowledge that Foxo is a nuclear target of Akt (274) and that Foxo-3a and Foxo-1 are negative regulators of myocyte hypertrophy (187, 245) requires a new look at the role of nuclear Akt in growth. Although the impact of NGF on cardiomyocyte size was not the objective of our recent study (36), we consider this issue of high relevance. Interestingly, NT-3, via trkC, reportedly promotes cardiomyocyte hypertrophy, possibly by acting on MAPK (128). We found that also trkB is expressed by rat neonatal cardiomyocytes (unpublished results), thus suggesting that BDNF may trigger responses in these cells. Further investigations are needed to improve our understanding of the full range of NT actions on the developing and adult cardiomyocytes.

Figure 8 illustrates the actions and signaling pathways emanating from trk receptors in the cardiomyocyte.

VI. NEUROTROPHINS IN CARDIOVASCULAR PATHOLOGY

A. Neurotrophins and Cancer Angiogenesis

Angiogenesis is essential for tumor development and metastasis. To initiate angiogenesis, tumor cells make an angiogenic switch by perturbing the local balance of pro- and antiangiogenesis factors and proteases (83). Being strong promoters of angiogenesis and able to activate VEGF-A and metalloproteases, NTs may contribute to the growth and diffusion of cancers (17, 72, 121, 188), even if this hypothesis has not been exhaustively validated, yet. It may be interesting to remember that the trk gene has
FIG. 7. Prosurvival activity of NGF on cardiac myocytes. 

A: Rat neonatal cardiomyocytes (RNMCs) express NGF and trkA. Immunofluorescence analysis shows the cardiac marker α-sarcomeric actin (green fluorescence) and NGF (red fluorescence) and merged images (costaining results in yellow fluorescence). B: NGF is an endogenous prosurvival factor for RNMCs. RNMCs were incubated for 48 h in serum-free medium with a goat-raised anti-NGF neutralizing antibody (Ab-NGF) or the trkA inhibitor K252a. Controls consisted of nonimmune goat serum (0.1% in PBS) or 0.1% DMSO, respectively. Apoptosis was detected by cleaved caspase-3 immunostaining (green fluorescence). Nuclei were counterstained by DAPI (blue fluorescence). The fluorescent images (×400) are representative of the experiment. Bar graph shows the percentage of cleaved caspase 3-positive RNMCs. Data are presented as means ± SE (n = 3). §P < 0.05 vs. 0.1% goat IgG; **P < 0.01 vs. 0.1% DMSO. 

C: NGF inhibits apoptosis in rat adult cardiomyocytes. A, isolated rat adult cardiomyocytes were maintained under normoxia or submitted to 6 h of hypoxia followed by 18 h reoxygenation and cotreated with NGF (50 ng/ml) or its vehicle PBS. Apoptotic nuclei were identified by TUNEL staining (green fluorescence). α-Sarcomeric actin stains cardiomyocytes (red fluorescence). The pictures were captured at ×400 magnification. Arrows point to TUNEL-positive cardiomyocytes. Bar graphs quantify apoptosis, which is expressed as percentage of TUNEL-positive cardiomyocyte. Data are presented as means ± SE (n = 3). *P < 0.05 vs. PBS plus H/R (B) D: Local NGF gene transfer prevents apoptosis of cardiomyocytes in the rat infarcted heart. Myocardial infarction was induced in adult Wistar rat. Ad.NGF or Ad.βGal (each at 10⁹ p.f.u.) was injected in the peri-infarct myocardium. After 7 days, the heart was arrested in diastole and perfusion fixed. Apoptosis of cardiomyocytes (CMs) was revealed by double staining for TUNEL (TUNEL-positive nuclei are stained in dark brown) and the cardiac marker α-sarcomeric actin (in purple). Nuclei were counterstained with hematoxylin. In the pictures captured (optical microscopy, ×1,000) from Ad.NGF and Ad.βGal specimens, TUNEL-positive apoptotic cardiomyocytes are pointed by arrows. Graph quantifies apoptosis of cardiomyocytes per mm² of peri-infarct myocardium section. Values are means ± SE (n = 7) *P < 0.05 vs. Ad.βGal. [From Caporali et al. (36).]
originally been cloned as an oncogene fused with the tropomyosin gene in the extracellular domain conferring constitutive activation of its tyrosine kinase activity to induce continuous cell proliferation (14, 180). Surprisingly, this gene was discovered to code for a high-affinity receptor for NGF (180). Trk receptors regulate growth, differentiation, and survival of tumors with neuronal origin, such as neuroblastoma and medulloblastoma (180). High expression of BDNF and trkB is considered a poor prognosis marker in neuroblastoma, one of the most common pediatric neoplasms (7, 169). Furthermore, trkB activation by BDNF, via HIF-1α and PI3K/mTOR, induces VEGF-A in neuroblastoma cells (183). In contrast, high expression of trkA is known to be a marker of good prognosis in the same tumor type (181). This discrepancy was explained in terms of the dependence of trkA-expressing neuroblastoma cells on NGF, which, when present in abundance, pushes them to mature or, when NGF is too low, to die (180). However, it was also shown that NGF-mediated activation of trkA decreases the content of proangiogenesis factors in the conditioned medium of neuroblastoma cells (74). Opposite results to neuroblastoma were found for medullary thyroid carcinoma (MTC). Compared with control cells, trkB-overexpressing MTC cells produce less VEGF-A in vitro and develop less and smaller cancers when implanted in mice, while trkA-overexpressing MTC cells give more VEGF-A and promote tumorigenesis and cancer growth in vivo (174).

Moreover, NGF is produced by hepatocellular carcinoma cells, and trkA was found expressed in the vascular walls of tumor-associated arteries, thus suggesting that NGF/trkA signaling may participate in cancer angiogenesis (137). Further support for this hypothesis comes from the finding that, in ovarian carcinoma, activated trkA is present on the EC membrane, both inside the tumor and in its vicinity (60). NGF is also produced by human melanomas (170), and both NT-3 and trkC are expressed by EC in or around human gliomas (32). In addition, malignant glioma-released NT-3 has the capacity to attract bone marrow-derived stroma cell (24), which may have implications for tumor vasculo genesis.

All these findings suggest the possibility that NTs can control cancer angiogenesis and consequently the growth and diffusion of primary tumors. However, a systemic evaluation of this concept was never developed, and cause-effect studies are especially important at this stage.

B. Neurotrophins and Angiogenesis Associated With Chronic Inflammation

Angiogenesis is intrinsic to psoriasis and arthritis. Psoriasis is a chronic inflammatory skin disorder characterized by accelerated proliferation and altered differentiation of keratinocytes and microvessels undergoing angiogenesis (57). NGF is produced by healthy and psoriatic epidermal keratinocytes and fibroblasts (4, 218), as well as by dermal microvascular EC (216). In a murine model
of cutaneous pressure ulcers, NGF promotes angiogenesis (95), thus accelerating wound healing (95). A similar wound closure effect by NGF has been reported in full-thickness skin wounds in mice (168). In a SCID mouse-human skin chimera xenograft model, NGF was seen to stimulate EC proliferation and induction of the intercellular adhesion molecule (ICAM-1) on EC (217, 219). In the same experimental model, either NGF neutralization or inhibition of trk receptors by K252a improved psoriasis (219). In addition, NGF upregulates the expression levels of substance P (155), which is a strong proangiogenesis inducer (285) involved in psoriasis (219). These findings, which need to be confirmed and expanded in future studies, suggest a role of NGF in psoriasis-associated angiogenesis. To the best of our knowledge, no report linking other NTs or their receptors to psoriasis are currently available.

Angiogenesis in the synovial membrane is considered an important early step in the pathogenesis and progression of inflammatory arthritis, particularly rheumatoid arthritis. Angiogenesis is required for the development of the rheumatoid pannus, which then leads to extensive synovial inflammation and joint destruction (133, 254). Consequently, it is relevant that NTs and their receptors are present at both mRNA and protein levels in inflamed peripheral joints of rheumatoid arthritis and spondyloarthritis patients (220). Both trkA and p75NTR are expressed in the endothelium of synovial tissue biopsy specimens obtained from clinically affected knee joints of patients with rheumatoid arthritis, spondyloarthritis, and osteoarthritis (220). Notably, NGF appears to be elevated in the synovial fluids of rheumatoid arthritis patients in comparisons with normal human synovial fluids (100). Investigations addressing the causative role of NTs in arthritis-linked angiogenesis have not been carried out.

C. Neurotrophins in Cardiovascular Inflammation, Atherosclerosis, and Vascular Wall Remodeling

Atherosclerosis is a complex, chronic inflammatory process of the arterial wall that involves the recruitment and activation of cells in a developing intimal lesion. Among the events triggering this process is the EC activation by inflammatory cytokines and oxidized lipoproteins, followed by the increased adhesion of blood-circulating monocytes to the activated endothelium and the migration of VSMC into a developing neointima. Then, lipid accumulation and modulation of vascular cell phenotypes by extracellular matrix proteins (especially metalloproteases) stimulate the development of an atherosclerotic plaque (140), which progressively obstructs the vascular lumen, thus reducing blood flow. The attempts to reestablish lumen patency by percutaneous transluminal angioplasty can result in the damage of the EC and the vascular internal elastic lamina, which in turn activates the shift of VSMC from a contractile to a synthetic phenotype and the VSMC migration to the lumen. This process culminates in neointima formation and restenosis of the vessel (186). Figure 9 illustrates the possible role played by NTs in neointima formation. Human and rat VSMC express NTs, p75NTR, and trk receptors in vivo and in culture (71, 141, 272). The expression levels of NGF, BDNF, trkA, and trkB are dramatically upregulated by arterial balloon injury in rats, and increased levels persist during neointima formation (71). BDNF, NT-3, NT-4/5,
trkB, trkC, and p75NTR were also found expressed in VSMC of human atherosclerotic lesions (71, 139), thus suggesting an implication of NTs in regulating VSMC response to vascular injury (71). This hypothesis is further supported by the knowledge that NGF promotes VSMC migration, via trkA (71, 141), while p75NTR stimulates VSMC apoptosis (139, 272). Furthermore, in VSMC, NGF induces the expression of the gelatinase MMP-9 (132), which has prominent activity against basement membrane components and becomes rapidly activated following mechanical injury (186). MMPs are major players in intimal thickening and atherosclerotic plaque development and rupture (186). Kraemer et al. (140) crossed trkB+/- with the atherosclerosis apolipoprotein E gene knock out mouse model (ApoE-/-) to find that reduction in trkB signaling slows the appearance of lipid deposition and neointima formation in mice fed with a proatherogenic diet (140). Unexpectedly, MMP-9 levels were identical in the vascular lesions of trkB+/ApoeE-/- and trkB+/ ApoE-/- mice (140). However, other matrix proteases might be regulated in their expression and activity by trkB. Bone marrow-derived inflammatory cells are less in vascular lesion developed by trkB+/ ApoE-/- mice compared with trkB+/- ApoE-/- mice. This difference could not be explained with the reduced trkB presence in bone marrow cells. In fact, results of experiments with bone marrow cross-transplantation between trkB+/- ApoE-/- and trkB+/- ApoE-/- mice disclaimed the importance of trkB presence in bone marrow for infiltration of inflammatory cells in atherosclerotic lesions (140). The latter finding is in apparent contradiction with another report of the same group, showing a prominent role of BDNF in stimulating mobilization of trkB+ Sca-1+ MOMA2+ from the bone marrow to engraft in tissue expressing high level of BDNF (131). We should not forget that BDNF/trkB activates an important prosurvival signaling for EC (135), and the integrity of luminal EC is fundamental to avoid adhesion of monocytes and to maintain VSMC in a contractile rather than proliferative status. Therefore, it is possible that the role of trkB in vascular wall remodeling and atherosclerosis is more complex. New models separately targeting trkB expression in EC, VSMC, and monocytes may provide more substantial information.

In support of a proinflammatory effect of trkB is a phage-display study, which identified increased trkB expression in the aging rodent heart (31). This was associated with functional studies revealing that age-associated alterations in the cardiac BDNF/trkB signaling enhance inflammation and increase myocardial injury after myocardial infarction in the aging heart (31). A role for BDNF in the pathogenesis of coronary artery disease has been also proposed (76). According to Ejiri et al. (76), BDNF derives mainly from diseased coronary arteries and contributes to plaque instability through enhancing local NADPH activity and superoxide production. These assumptions derived from finding higher BDNF concentrations in the EDMA-containing plasma of the coronary sinus than in the aortic root of patients with acute coronary syndrome (76). However, high levels of BDNF are stored in human platelets. Increased blood flow velocity and shear stress in the presence of significant narrowing of epicardial coronary arteries lead to platelet activation, and this may justify the BDNF released in the circulation. Therefore, it is possible that BDNF is not released by diseased vessels, but by activated platelets (158). It is also possible that, since BDNF is a prosurvival factor for EC, diseased vessels increase its production and release for their self-protection.

D. p75NTR-Induced Impairment in Postischemic Reparative Neovascularization in Diabetes

Type 1 diabetes downregulates the content of NGF and trkA in ischemic skeletal muscles and concomitantly induces p75NTR expression in capillary EC (35, 36, 229) (see Fig. 10A). Recent data from our group provide evidence that p75NTR is responsible for diabetes-induced impairment in neovascularization of ischemic limb muscles. In fact, when diabetic mice were treated with an adenovirus carrying a dominant negative p75NTR mutant form in their ischemic limbs, the postischemic angiogenesis process and blood perfusion recovery were normalized to levels similar to what was observed in normoglycemic mice (see Fig. 10B) (35). Interestingly, NGF supplementation, rather than initiating apoptosis of diabetic EC via p75NTR, downregulates p75NTR expression, by a mechanism which has not yet not been clarified, and promotes EC survival and vascular regeneration (95, 229).

VII. NEUROTROPHIN-BASED THERAPEUTIC PERSPECTIVES

As illustrated above, NTs can promote reparative neovascularization. Therefore, NTs could be of therapeutic value for ischemic diseases, such as peripheral ischemia and myocardial infarct, which would benefit from strategies able to improve blood flow. Moreover, because of their capacity to promote neuroprotection and neurogenesis together with cardiovascular protection and angiogenesis, we consider NTs particularly appealing for treatment of conditions in which both microangiopathy and neuropathy are pathogenetically involved. This is the case, for example, of the diabetic foot. Loss of nociception, axon-reflex vasodilation, and microangiopathy leading to ischemia contribute to cutaneous ulceration in diabetic subjects. Interestingly, NGF, which is trophic to sensory and sympathetic fibers, is reduced in diabetic nerves, and endogenous NGF deprivation results in hy-
poalgesia (3, 5). NGF, BDNF, and NT-3 have all been found to be reduced in early diabetic neuropathy skin (3). Recombinant NGF has been tested in a clinical trial of diabetic polyneuropathy, showing promise at the phase II level (8). Unfortunately, the only phase III trial attempted to date showed negative results, which stopped the investigation, even when the trial design had been questioned (8). Nevertheless, cases of diabetic patients with limb
ulcers unresponsive to conventional therapies responding positively to topical application of NGF have been described (90). Moreover, NGF-based therapy proved beneficial for stimulating angiogenesis and healing of skin wounds in diabetic mice (95). NGF additionally showed the potential to cure several forms of skin ulcers in humans, such as foot pressure ulcers (144), ischemic skin lesion of the foot in a child with Crush syndrome (48), and chronic vasculitic ulcers associated with rheumatoid arthritis (262). In all these cases, even if it was not specifically assessed, it is possible that NGF-induced neoangiogenesis may have contributed to the healing action of the NT. NGF additionally proved its ability to treat neurotrophic (25, 143) and herpetic corneal ulcer (171).

The diabetic heart is also expected to benefit from NGF supplementation. In fact, the diabetic heart suffers from exaggerated apoptosis of cardiomyocytes and vascular cells (223), which NGF is able to combat (78, 229). Furthermore, a main cause of sudden death in diabetes is silent myocardial ischemia, caused by cardiac sensory nerve impairment. Ieda et al. (118) interestingly demonstrated that NGF is critical for cardiac sensory innervation and that NGF gene therapy to the heart rescues neuropathy in diabetic rats.

Another clinical condition in which we foresee a particular potential for NT-based therapies is erectile dysfunction, where neurogenic and vasculogenic causes are both involved. Diabetes and hypercholesterolemia are possible causes of erectile dysfunctions. NTs and receptors are expressed by penis-projecting neurons of the major pelvic ganglion as well as by penile sensory neurons, which are all involved in erections (110). Angiogenesis gene therapy of the corpus cavernous with VEGF-A and angiopoietin-1 has been recently shown to improve erectile function in hypercholesterolemic rats (227), thus anticipating the possibility that proangiogenic NTs may be ideal drug candidates for treating this disabling condition. In agreement, NT-3 delivery to the cavernous nerve of type 1 diabetic rats significantly enhances intracavernous pressure (16), which may have been partially due to neoangiogenesis under the stimulation of secreted NT-3. Moreover, combined VEGF-A and BDNF improved the erectile response in a nerve-crush rat model (114) and in erectile dysfunction induced by hyperlipidemia (93). Also in these cases, the proangiogenesis action of NTs may have played a role.

NTs are not considered good drug candidates, because of their poor pharmacokinetic behavior and, in case the target is the brain, lack passage across the blood-brain barrier. Moreover, NTs, even if with lower affinity than pro-NTs, can still activate the proapoptotic p75NTR (153, 232). Some of these considerations may in part justify the partial disappointment with the trial using recombinant NGF in diabetic neuropathy (8). Apart from gene therapy or cell-based gene delivery, alternative strategies to the use of NT proteins may consist of using small molecule activators of trks. Recently, cell-permeable small compounds able to activate trkA (but not p75NTR) in the absence of NGF have been developed starting from the screening of libraries of asterriquinones and monoindol-quinones using a 96-well enzyme-linked immunosorbant assay that detects phosphorylated trkA (153). By similar or alternative approaches, small molecule agonists for trkB and trkC could be developed for antiapoptosis and proangiogenesis therapies. The same experimental platform could be also exploited to develop antagonist compounds able to block NT-induced activation of trks. In this case, the obvious therapeutic target would be represented by pathological angiogenesis associated with neoplastic pain and inflammation, such as arthritis and psoriasis, or cancer. In addition, the team led by Longo and Massa (159) has prepared NGF small molecule mimetics, able to act selectively at p75NTR or trkA receptors and activate partially distinct patterns of intracellular signaling cascades, compared with those activated by NGF. Of these molecules, the ones selectively activating trkA may deserve to be tested for the ability to promote angiogenesis in ischemic tissues. Moreover, trk function can also be improved by inhibition of protein-tyrosine phosphatase (279). Conversely, small molecules able to sequestre NTs, thus impeding interaction with their receptors, could have a scope in pathological angiogenesis. This may be the case for the recombinant domain 5 of trkA (trkAd5), which binds to NGF, thus inhibiting NGF action (61). TrkAd5 showed a therapeutic potential in preclinical models of inflammatory pain and asthma (61). In general, drugs able to block trk signaling at receptorial or postreceptorial level might have a role in inhibiting angiogenesis.

VIII. SUMMARY AND PERSPECTIVES

In this review, we have described the components of the NTs family, showing that mature NTs and proforms of NTs can bind, with different affinities, to two receptor types: the tropomyosin kinase receptors (trks) and the p75NTR. We have reported expression of both types of receptors by cardiovascular cells, which is an essential prerequisite for direct cardiovascular actions of NTs. We have also described the signaling mechanisms downstream of NT receptors. The first hints of the existence of direct cardiovascular actions of NTs stemmed from pioneering work on development of mice with global gene knockout for NT-3, trkC, BDNF, and trkB. These studies, together with more recent data on the role of NTs in cardiovascular development and stem cell differentiation into the angiomyogenic lineage, have been extensively described by this review. Next, we have illustrated the roles of NTs in cardiovascular physiology during adult-
hood. In developing and adult organisms, endogenous NTs control the growth and maintenance of blood vessels as well as the survival of cardiac myocytes. On the other side, NTs can also participate in pathological events, such as cancer angiogenesis and angiogenesis associated with other situations of chronic inflammation (psoriasis, arthritis, etc.). NTs also contribute to atherosclerosis and vascular wall remodeling following intraluminar vascular injury or changes in blood flow. Recent data from our laboratory provide novel evidence that p75NTR induces EC apoptosis and cycle arrest and contributes to diabetes-induced impairment in reparative angiogenesis following induction of peripheral ischemia (35). We have finally discussed potential disease targets that can benefit from therapies based on NTs, NT-mimetic, and enhancers of trk receptor actions to promote cardiovascular protection or, vice versa, trk inhibition or antagonism to arrest pathological angiogenesis.

We hope that this review will serve to encourage additional research in the cardiovascular actions of NTs.

ACKNOWLEDGMENTS

This review contains unpublished data from Dr. Marco Meloni, Dr. Elisabetta Pani, Brunella Cristofaro, and Paola Campagnolo, who are present or past PhD students or post docs at the Experimental Cardiovascular Medicine Division of the Bristol Heart Institute. We thank Prof. Paolo Madeddu and Prof. Saadeh Suleiman (both from our same institute) for revision of the manuscript.

Address for reprint requests and other correspondence: C. Emanueli, Bristol Heart Institute, Univ. of Bristol, Bristol Royal Infirmary, Level 7, Upper Maudlin Rd., BS2 8HW Bristol, UK (e-mail: Costanza.Emanueli@bristol.ac.uk or c.emanueli@yahoo.co.uk).

GRANTS

C. Emanueli holds a British Heart Foundation (BHF) Basic Science Lectureship (RFLS. Rj4430) and is Reader in Experimental Cardiovascular Medicine at the University of Bristol. A. Caporali is a BHF PhD student (RFLS. Sm6266). Their laboratory is a member of the European Vascular Genomic Network of Excellence.

REFERENCES


CARDIOVASCULAR ACTIONS OF NEUROTROPHINS


264. Urra S, Escudero CA, Ramos P, Lisbofa, Allende E, Covarrubias P, Parraegue JI, Zampieri N, Chao MV, Annaert W, Bronfman FC. TrkA receptor activation by nerve growth factor induces shedding of the p75 neurotrophin receptor followed by...
endosomal gamma-secretase-mediated release of the p75 intracel-

265. Van der Zee CE, Ross GM, Riopelle RJ, Hagg T. Survival of
cholinergic forebrain neurons in developing p75NGFR-deficient

266. Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R,
Driscoll PC, Woscholski R, Barker PA, Moscat J. The atypical protein kinase C-interacting
protein p62 is a scaffold for NF-kappaB activation by nerve growth factor.

267. Wright JH, Drueckes P, Bartoe J, Zhao Z, Shen SH, Krebs EG.
A role for the SHP-2 tyrosine phosphatase in nerve growth-induced

268. Xie Y, Massa SM, Enslen-Craig SE, Major DL, Yang T, Tisi
MA, Derevyannyy VD, Runge WO, Mehta BP, Moore LA, Brady-
Kalanay SM, Longo FM. Protein-tyrosine phosphatase (PTP) 
 wedge domain peptides: a novel approach for inhibition of PTP 
 function and augmentation of protein-tyrosine kinase function.

269. Yamada M, Ohnishi H, Sano S, Araki T, Nakatani A, Ikeuchi T,
Hatano H. Brain-derived neurotrophic factor stimulates interactions 
 of Shp2 with phosphatidylinositol 3-kinase and Grb2 in 

270. Yamashita T, Tohyama M. The p75 receptor acts as a displacement 
 factor that releases Rho from Rho-GDI. Nat Neurosci 6: 

271. Yamashita T, Tucker KL, Barde YA. Neurotrophin binding to the 
p75 receptor modulates Rho activity and axonal outgrowth. 

272. Yeiser EC, Rutkoski NJ, Naito A, Inoue J, Carter BD. Neuro-
trophin signaling through the p75 receptor is deficient in traf6/
H11002

273. Yoon SO, Casaccia-Bonnefil P, Carter B, Chao MV. Competitive 
signaling between TrkA and p75 nerve growth factor receptors 

274. Ziche M, Morbidelli L, Masini E, Amerini S, Granger HJ, 
Maggi CA, Geppetti P, Ledda F. Nitric oxide mediates angiogen-
esis in vivo and endothelial cell growth and migration in vitro 

275. Zupan AA, Osborne PA, Smith CE, Siegel NR, Leimgruber RM,
Johnson EM Jr. Identification, purification, and characterization of truncated forms of the human nerve growth factor receptor. 

276. Zwick E, Wallasch C, Daub H, Ulrich A. Distinct calcium-
dependent pathways of epidermal growth factor receptor transac-
tivation and PYK2 tyrosine phosphorylation in PC12 cells. J Biol 